Since September, 100 drugs have been suspended or withdrawn from the market

[industry trends of pharmaceutical network] since September, there have been many news that the purchase of drugs has been suspended in Liaoning, Jiangsu and other places, and the number is not small The main reasons include: there are more than three manufacturers that have passed the consistency evaluation for the same kind of drugs, so they are no longer selected for centralized purchase of drugs This is also a national policy Through consistency evaluation, only the tickets to participate in the competition can the top three companies have access to the market In addition, failure to pass the consistency evaluation, unwillingness to reduce the price, non-compliance and other reasons will also be suspended from the procurement qualification, or withdraw from the market Liaoning: 177 drugs were suspended from purchasing On October 14, Liaoning Public Resources Trading Center issued two notices in succession, which made clear the purchase of drugs for consistency evaluation again If there are more than three enterprises that have passed the consistency evaluation for the same kind of drugs (in terms of specifications), and other drugs that have not passed the consistency evaluation have been purchased online on the drug centralized purchase platform of Liaoning Province, the qualification for online purchase shall be suspended According to the notice, as many as 177 drugs have been suspended from purchasing, involving 105 pharmaceutical companies Jiangsu: 133 drugs were suspended from purchasing On October 16, Jiangsu public resources trading center issued the notice on suspending purchasing drugs that failed to pass the conformity assessment of quality and efficacy of generic drugs As more than three manufacturers of the same drug variety passed the conformity assessment, 133 drugs were suspended from purchasing Sichuan: four drugs were disqualified from purchasing On October 8, the industry learned from the Sichuan provincial pharmaceutical machinery purchasing center that four drugs were stopped from purchasing online According to a series of drug quality announcements issued by the State Drug Administration in the early stage, the four drugs are due to unqualified sampling According to the relevant regulations, the relevant production enterprises are listed in the general bad records, and the qualification and results of these four drugs participating in the centralized classified procurement in Sichuan Province are cancelled Shanghai: the purchasing qualification of six drugs was suspended On September 17, Shanghai Sunshine purchasing center announced the notice on suspending the purchasing qualification of some drugs According to the relevant notice issued by the State Food and drug administration, the purchasing qualification of six drugs will be suspended from September 18, 2019 Among them, three specifications of Xidi lozenge are listed It is reported that most of the drugs suspended from purchasing this time are competitive drugs Taking Muxiang SHUNQI pill as an example, according to incomplete statistics, there are as many as 16 manufacturers Zhejiang: products without price adjustment will be suspended from online trading On October 11, Zhejiang Pharmaceutical machinery purchase platform issued the notice on publicizing the price complaint handling results of some online products of centralized purchase of drugs in our province, which made it clear that in the process of online transaction of centralized purchase of drugs, the national low price linkage was carried out, and for the products of enterprises in the catalogue of products to reduce the price of online transaction, which were complained about due to price and other reasons, relevant products were ordered After the national low price is generated, the price should be lowered, and the varieties that refuse to adjust the price will be given the treatment measures of "suspending online transactions" Qinghai: clearly no higher than the current national low provincial purchase price Coincidentally, on October 11, the centralized procurement network of drugs and medical consumables of Qinghai Province released the notice on publicizing the information review and comprehensive scoring results of products of centralized procurement of drugs in 2019 in Qinghai Province, and also published the list of information review results of products of centralized procurement of drugs (key monitoring) in 2019 According to the purchase rules, for the key monitored drugs with large purchase quantity and high purchase amount, "they shall not be higher than the current national low provincial purchase price" It can be seen that the situation of national linkage of purchasing results with volume is becoming increasingly clear, and drug companies either "cut the meat" or "get out".